Vitality Portfolio
Vitality Portfolio reported 31 holdings worth US$2.14M as of Mar 31, 2026 (Form N-PORT)
As of Mar 31, 2026 · Filed May 28, 2026
Vitality Portfolio reported 31 holdings worth US$2.14M as of Mar 31, 2026. Largest: Argenx Se, Eli Lilly And Company and Ascendis Pharma A/s. Filed May 28, 2026 (Form N-PORT).
- Holdings
- 31
- Value as reported
- US$2.14M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Argenx Se | 235 | US$172K | 8.0% |
| Eli Lilly And Company | 181 | US$166K | 7.8% |
| Ascendis Pharma A/s | 512 | US$117K | 5.5% |
| Nektar Therapeutics | 1,412 | US$102K | 4.8% |
| Thermo Fisher Scientific Inc | 186 | US$91,425 | 4.3% |
| Align Technology, Inc. | 521 | US$89,315 | 4.2% |
| Enliven Therapeutics, Inc. | 2,126 | US$83,339 | 3.9% |
| 10x Genomics, Inc. | 3,801 | US$80,695 | 3.8% |
| Newamsterdam Pharma Company N.v. | 2,383 | US$76,280 | 3.6% |
| Ceribell, Inc. | 3,915 | US$71,762 | 3.4% |
| Doximity, Inc. | 2,688 | US$62,630 | 2.9% |
| Intuitive Surgical, Inc. | 132 | US$60,851 | 2.8% |
| Guardant Health, Inc. | 631 | US$58,285 | 2.7% |
| Alnylam Pharmaceuticals, Inc. | 175 | US$57,902 | 2.7% |
| Vertex Pharmaceuticals Incorporated | 128 | US$57,157 | 2.7% |
| Vaxcyte, Inc. | 952 | US$55,321 | 2.6% |
| Illumina, Inc. | 437 | US$53,865 | 2.5% |
| Inspire Medical Systems, Inc. | 1,030 | US$53,127 | 2.5% |
| Zoetis Inc. | 411 | US$48,584 | 2.3% |
| Unitedhealth Group Incorporated | 172 | US$46,541 | 2.2% |
| Kymera Therapeutics, Inc. | 534 | US$44,477 | 2.1% |
| Dexcom, Inc. | 677 | US$42,516 | 2.0% |
| Beam Therapeutics Inc. | 1,602 | US$38,176 | 1.8% |
| West Pharmaceutical Services, Inc. | 146 | US$36,593 | 1.7% |
| Ataibeckley Inc. | 9,857 | US$34,894 | 1.6% |
| Maxcyte, Inc. | 49,461 | US$34,746 | 1.6% |
| Veeva Systems Inc. | 190 | US$33,375 | 1.6% |
| Schrodinger, Inc. | 2,552 | US$28,991 | 1.4% |
| Tempus Ai, Inc. | 577 | US$26,092 | 1.2% |
| Ultragenyx Pharmaceutical Inc. | 758 | US$15,880 | 0.74% |
| Uniqure N.v. | 746 | US$12,197 | 0.57% |
Source
View original at SEC
Related